Abstract
1/2022
vol. 9
Review paper
Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review
- Department of Immunopathology, Medical Faculty, Medical Univesity of Lodz, Lodz, Poland
Alergologia Polska – Polish Journal of Allergology 2022; 9, 1: 33–40
Online publish date: 2022/03/09
COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.
Keywords
COVID-19, drugs, oral, pills, molnupiravir, beta-d-N4-hydroxycitidine, eidd-2801, mk4482, baricitinib, ritonavir, PF-07321332, nirmatrelvir
Coverage in
Integrated with


